EFFECTS OF RESMETIROM (MGL-3196) ON HEPATIC FAT, LIPIDS, LIVER ENZYMES AND MARKERS OF LIVER FIBROSIS IN AN OPEN-LABEL 36-WEEK EXTENSION STUDY IN NASH PATIENTS
Publication
, Conference
Harrison, SA; Bashir, M; Moussa, S; Taub, RA; Frias, JP; Alkhouri, N
Published in: HEPATOLOGY
October 1, 2019
Duke Scholars
Published In
HEPATOLOGY
EISSN
1527-3350
ISSN
0270-9139
Publication Date
October 1, 2019
Volume
70
Start / End Page
169A / 170A
Location
Boston, MA
Publisher
WILEY
Conference Name
Annual Meeting of the American-Association-for-the-Study-of-Liver-Diseases (AASLD) / Liver Meeting
Related Subject Headings
- Gastroenterology & Hepatology
- 3204 Immunology
- 3202 Clinical sciences
- 1107 Immunology
- 1103 Clinical Sciences
- 1101 Medical Biochemistry and Metabolomics
Citation
APA
Chicago
ICMJE
MLA
NLM
Harrison, S. A., Bashir, M., Moussa, S., Taub, R. A., Frias, J. P., & Alkhouri, N. (2019). EFFECTS OF RESMETIROM (MGL-3196) ON HEPATIC FAT, LIPIDS, LIVER ENZYMES AND MARKERS OF LIVER FIBROSIS IN AN OPEN-LABEL 36-WEEK EXTENSION STUDY IN NASH PATIENTS. In HEPATOLOGY (Vol. 70, pp. 169A-170A). Boston, MA: WILEY.
Harrison, Stephen A., Mustafa Bashir, Sam Moussa, Rebecca A. Taub, Juan Pablo Frias, and Naim Alkhouri. “EFFECTS OF RESMETIROM (MGL-3196) ON HEPATIC FAT, LIPIDS, LIVER ENZYMES AND MARKERS OF LIVER FIBROSIS IN AN OPEN-LABEL 36-WEEK EXTENSION STUDY IN NASH PATIENTS.” In HEPATOLOGY, 70:169A-170A. WILEY, 2019.
Harrison SA, Bashir M, Moussa S, Taub RA, Frias JP, Alkhouri N. EFFECTS OF RESMETIROM (MGL-3196) ON HEPATIC FAT, LIPIDS, LIVER ENZYMES AND MARKERS OF LIVER FIBROSIS IN AN OPEN-LABEL 36-WEEK EXTENSION STUDY IN NASH PATIENTS. In: HEPATOLOGY. WILEY; 2019. p. 169A-170A.
Harrison, Stephen A., et al. “EFFECTS OF RESMETIROM (MGL-3196) ON HEPATIC FAT, LIPIDS, LIVER ENZYMES AND MARKERS OF LIVER FIBROSIS IN AN OPEN-LABEL 36-WEEK EXTENSION STUDY IN NASH PATIENTS.” HEPATOLOGY, vol. 70, WILEY, 2019, pp. 169A-170A.
Harrison SA, Bashir M, Moussa S, Taub RA, Frias JP, Alkhouri N. EFFECTS OF RESMETIROM (MGL-3196) ON HEPATIC FAT, LIPIDS, LIVER ENZYMES AND MARKERS OF LIVER FIBROSIS IN AN OPEN-LABEL 36-WEEK EXTENSION STUDY IN NASH PATIENTS. HEPATOLOGY. WILEY; 2019. p. 169A-170A.
Published In
HEPATOLOGY
EISSN
1527-3350
ISSN
0270-9139
Publication Date
October 1, 2019
Volume
70
Start / End Page
169A / 170A
Location
Boston, MA
Publisher
WILEY
Conference Name
Annual Meeting of the American-Association-for-the-Study-of-Liver-Diseases (AASLD) / Liver Meeting
Related Subject Headings
- Gastroenterology & Hepatology
- 3204 Immunology
- 3202 Clinical sciences
- 1107 Immunology
- 1103 Clinical Sciences
- 1101 Medical Biochemistry and Metabolomics